BCRX compared with MNPR: revenue, margins and what each company keeps, and the suppliers and customers both name

BCRXBiocryst Pharmaceuticals Inc

Mkt capRevenueRevenue

MNPRMonopar Therapeutics

Mkt capRevenueRevenue

Compare

BCRXBiocryst Pharmaceuticals Inc

MNPRMonopar Therapeutics

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

MNPR: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only BCRX 1

—Specialty pharmacy providerunlistedsupplier

Shared 0

No shared counterparties.

Only MNPR 2

AZNAstraZenecasupplier

—NorthStarunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

BCRX, solidMNPR, dashed

BCRXBiocryst Pharmaceuticals Inc

8.25▼−2.64%

Mkt cap$2.2BRevenue$218MQ2 FY26Revenue$875MFY25

MNPRMonopar Therapeutics

67.15▼−4.51%

Regular sessionSep 2 '83

Mkt cap$472.0MRevenue—Revenue—

Compare

Regular sessionSep 2 '83

BCRXBiocryst Pharmaceuticals Inc

MNPRMonopar Therapeutics

8.25▼−2.64%

Price

67.15▼−4.51%

$2.2B

Mkt cap

$472.0M

Q2 FY26$218M

Revenue

—

FY25$875M

Revenue

—

BCRX8.25▼−2.64%vsMNPR67.15▼−4.51%Regular sessionSep 2 '83